AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00806598
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
Trial: NCT03796598
Drug: Fecal Microbial Transplant Enema
RxNorm normalized name: fecal microbiota, live Enema
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT enema
Trial: NCT01510132
Drug: Travoprost/timolol fixed combination (Travacom)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT00520871
Drug: Blueberry juice
RxNorm normalized name: lowbush blueberry juice
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05489939
Drug: The compound methyl salicylate liniment
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
Trial: NCT00357318
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01837797
Drug: Brexpiprazole 1 mg
RxNorm normalized name: brexpiprazole 1 MG
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily dose, tablets, orally
Trial: NCT01837797
Drug: Brexpiprazole 3 mg
RxNorm normalized name: brexpiprazole 3 MG
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily dose, tablets, orally
Trial: NCT00004758
Drug: carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004758
Drug: corticotropin
RxNorm normalized name: Corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004758
Drug: nitrazepam
RxNorm normalized name: nitrazepam
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004758
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04528290
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ozanimod capsule formulation of 0.92mg
Trial: NCT04528290
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ozanimod, granule formulation of 0.92mg
Trial: NCT04348006
Drug: Bortezomib 3.5 MG
RxNorm normalized name: bortezomib 3.5 MG
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)
Trial: NCT01085292
Drug: NOX-E36
RxNorm normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
Trial: NCT01085292
Drug: NOX-E36
RxNorm normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
Trial: NCT02854670
Drug: Capsaicin patch
RxNorm normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
Trial: NCT04381936
Drug: Lopinavir-Ritonavir
RxNorm normalized name: lopinavir-ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
Trial: NCT04381936
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
Trial: NCT04381936
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
Trial: NCT04381936
Drug: Synthetic neutralising antibodies
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
Trial: NCT04381936
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
Trial: NCT04381936
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
Trial: NCT04381936
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
Trial: NCT04381936
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
Trial: NCT00557349
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
Trial: NCT04381936
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
Trial: NCT04381936
Drug: High Dose Corticosteroid
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
Trial: NCT00557349
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
Trial: NCT00005968
Drug: irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750178
Drug: vorinostat (MK0683 )
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days
Trial: NCT04381936
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
Trial: NCT00567957
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: same volume iv bolus before induction followed by same volume infusion
Trial: NCT04381936
Drug: Sotrovimab
RxNorm normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
Trial: NCT04381936
Drug: Molnupiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
Trial: NCT04381936
Drug: Paxlovid
RxNorm normalized name: Paxlovid
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
Trial: NCT04381936
Drug: Baloxavir Marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.
Trial: NCT04381936
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)
Trial: NCT04381936
Drug: Low-dose corticosteroids: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Trial: NCT04381936
Drug: Low-dose corticosteroids: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Trial: NCT04399356
Drug: Niclosamide
RxNorm normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
Trial: NCT01540565
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03254160
Drug: DNS-3379
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNS-3379
Trial: NCT04996290
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthetic used for peripheral nerve block.
Trial: NCT00058682
Drug: Anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04107428
Drug: Somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
Trial: NCT00778518
Drug: ARX201
RxNorm normalized name: ARX201
DrugBank: ARX201 (DB05082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
Trial: NCT00778518
Drug: ARX201
RxNorm normalized name: ARX201
DrugBank: ARX201 (DB05082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
Trial: NCT03052816
Drug: Ice T
RxNorm normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ice/Tylenol/Toradol with dilaudid for breakthrough
Trial: NCT01000025
Drug: PF-00299804
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-804 45 mg PO, daily
Trial: NCT00778518
Drug: ARX201
RxNorm normalized name: ARX201
DrugBank: ARX201 (DB05082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
Trial: NCT01361373
Drug: L- DOPA
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
Trial: NCT02768415
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02768415
Drug: Oral Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00612157
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3mg orally at bedtime for 14 nights
Trial: NCT03918447
Drug: Bardoxolone methyl oral capsule
RxNorm normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
Trial: NCT02193308
Drug: Telmisartan/Amlodipine FDC
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02193308
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02193308
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02469519
Drug: Betamethasone - ACTIVE
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
Trial: NCT00305500
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01625923
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
Trial: NCT00820417
Drug: Cetuximab/Gefitinib combination and/or monotherapy
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01735942
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002517
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002517
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002517
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002517
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002517
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002517
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002517
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259894
Drug: BIRT 2584 XX
RxNorm normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00975052
Drug: sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg sitagliptin daily for two days in one out of four treatment periods
Trial: NCT00975052
Drug: Comparator: metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
Trial: NCT02748902
Drug: ingenol mebutate 0.05% gel
RxNorm normalized name: INGENOL MEBUTATE 0.05% GEL,TOP
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
Trial: NCT00564564
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
Trial: NCT00564564
Drug: Clomipramine
RxNorm normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
Trial: NCT03377725
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration
Trial: NCT03377725
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.16mg/kg,d1-5,ivgtt,28days as a duration
Trial: NCT00975052
Drug: Comparator: sitagliptin and metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
Trial: NCT01083420
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.01% mouthwash
Trial: NCT00965796
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 2 mg/kg/h- during surgical procedure Saline
Trial: NCT01422369
Drug: Pitavastatin (NK-104)
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin (NK-104) 4mg once daily (QD)
Trial: NCT01422369
Drug: Darunavir/Ritonavir (Prezista)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir/Ritonavir (Prezista) 800 mg/100 mg
Trial: NCT00219778
Drug: mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00435981
Drug: rhGAD65 formulated in Alhydrogel® (Diamyd®)
DrugBank: rhGAD65 (DB04963)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02956278
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004113
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00387036
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
Trial: NCT00767767
Drug: Propofol 0.45mcg/mL
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Propofol infusion for 2 hours.
Trial: NCT00767767
Drug: Propofol 0.90mcg/mL
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Propofol infusion for 2 hours.
Trial: NCT00767767
Drug: Thiopental 1.5mcg/mL
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Thiopental 1.5mcg/mL infusion for 2 hours
Trial: NCT00767767
Drug: Thiopental 3mcg/mL
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Thiopental 3mcg/mL infusion for 2 hours
Trial: NCT01678820
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg tablet
Trial: NCT01678820
Drug: Placebo to sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching placebo to sitagliptin 100 mg tablet